Clinical Brief: IL-13 inhibitors: Advances and Considerations for Managing Moderate-to-Severe Atopic Dermatitis
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions. However, the treatment of AD is a clinical challenge. Although in many patients AD symptoms can be controlled primarily with topical agents, long-term treatment for moderate-to-severe patients can be challenging or may not be adequately addressed. Targeted immunomodulatory agents, based on recent advances in the understanding of AD pathophysiology, represent additional options for long-term control. There are currently two IL-13 inhibitor therapies, dupilumab (IL-4/13) and tralokinumab, approved by the FDA for treatment of moderate-to-severe AD, and more in late-stage clinical development.
It is imperative that clinicians understand the role of the IL-13 cytokine pathway in AD pathogenesis as more therapies emerge to target this cytokine in an effort to provide long-term, efficacious treatment. This clinical brief is designed to deliver succinct education about these emerging targeted treatments and why targeting the IL-13 pathway may be more effective than current treatment options, thereby helping clinicians to improve their knowledge and competence in treating patients with moderate-to-severe AD.
This activity is designed to target US-based physicians, nurses and professional staff members of medical practices specializing in dermatology as well as nurses, nurse practitioners, physician assistants, and pharmacists.
- Review the mechanism of action behind IL-13 inhibitors as a targeted treatment for AD
- Interpret the clinical safety and efficacy data for current and emerging IL-13 inhibitors for AD
- Develop individualized treatment plans for moderate-to-severe AD patients who would be candidates for treatment with an IL-13 inhibitor
Christopher G. Bunick, MD, PhD
Associate Professor of Dermatology
Peter A. Lio, MD
Partner at Medical Dermatology Associates
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires all individuals who are in a position to control the content of this activity to disclose all their financial relationships with ineligible companies. All identified COI are thoroughly mitigated according to the Annenberg Center for Health Sciences at Eisenhower’s policy. The Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ACCME-defined ineligible company.
|Christopher Bunick, MD, PhD||Consultant||Almirall, LEO, UCB|
|Speaker||Allergan, Almirall, UCB|
|Peter Lio, MD||Advisor||Almirall, ASLAN Pharmaceuticals, Concerto Biosciences, Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO, AbbVie, Eli Lilly, Micreos, Lipidor, L'Oreal, Pierre-Fabre, Johnson & Johnson, Castle Biosciences, Level Ex, Boston Skin Science (KPAway), Unilever, Menlo Therapeutics, Theraplex, Kaleido Biosciences, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, YobeeCare, Burt's Bees, My-Or Diagnostics, and Kimberly Clark|
|Individual stocks and options||Micreos, YobeeCare, Altus Labs, Boston Skin Science (KPAway), Concerto Biosciences|
|Royalties or patent beneficiary||Theraplex AIM (Theraplex company) patent|
|Speaker||Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, Incyte, and L'Oreal|
All of the relevant financial relationships listed for these individuals have been mitigated.
The planners and others reported the following financial relationships or other relationships they have with ACCME-defined ineligible companies related to the content of this continuing education activity:
The content manager, Amy Kousouros, from LiVDerm, has nothing to disclose.
The PIM planners and others have nothing to disclose.
All staff at the Annenberg Center for Health Sciences at Eisenhower involved in this activity have no relationships to disclose.
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and LiVDerm in collaboration with Postgraduate Institute for Medicine.
Estimated time to complete activity: 15 minutes
This activity is supported by an educational grant from LEO Pharma.
Physician Continuing Medical Education
In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center), the Postgraduate Institute for Medicine (PIM) and Tarsus Cardio Inc. dba LivDern. Annenberg Center and PIM are both jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Annenberg Center for Health Sciences at Eisenhower designates this Enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
PIM designates this live activity for a maximum of 0.25 ANCC contact hours.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you have questions regarding the certification of this activity, please contact Annenberg via email at firstname.lastname@example.org
Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.
A computer or device with an internet connection.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC
- 0.25 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.